AstraZeneca

Open: 64.28 Close: 64.13 Change: -0.15

What an AI can tell you about AstraZeneca before investing.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, drug, Sanofi, treatment, US, therapy, disease, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

British drugmaker AstraZeneca (AZN) is proudly touting the success of two of its experimental breast cancer drugs in separate clinical trials. Truqap in combination with Faslodex (fulvestrant) for the treatment of the most common type of breast cancer. Company plans to auction off Bangalore site “in a fully operational manner” to buyer.

Today's News

CDC expedites release of Sanofi, AstraZeneca drug amid shortage of RSV. Beyfortus, a monoclonal antibody from Sanofi and AstraZeca that won approval in August, is one of two available treatments in the U.S. AstraZeneca has the potential to develop a market-leading oral therapy that addresses multiple cardiometabolic diseases, including obesity and cardio-renal disease. There are significant opportunities for Astra Zeneca in T2D and hypertension. Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of the most common type of breast cancer. FDA based its decision on results from the Phase III CAPItello-291 trial. AstraZeneca takes $245 million step towards future of gene therapy. British drugmaker AstraZeneca (AZN) is proudly touting the success of two of its experimental breast cancer drugs in separate clinical trials. The partnership with Cellectis (Cellectis) is a key player in the development of cutting-edge therapeutic. Astrazeneca PLC ADR rises Friday, outperforms market - MarketWatch. AstraZeneca PLS ADR AZN inched 0.52% higher to $64.13 Friday, on what proved to be an all-around great trading session. AstraZeneca CEO Pascal Soriot and supply chain apprentice Kate Stevenson reflect on their motivations to prioritise our sustainability efforts. AstraZeneca PLC has 1,550m shares in circulation. The share turnover, otherwise know as daily liquidity, is 0.07%. AstraZeneca: Truqap Plus Faslodex approved in US for HR+ Breast Cancer. Company plans to auction off Bangalore site “in a fully operational manner” to a buyer who can also serve as a contract manufacturer for Astra Zeneca drugs made and packaged in Bangalore. AstraZenecas Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade) Nathan Aisenstadt: Solid Earnings Report Reinforces Medium To Long-Term Upside.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, drug, Sanofi, treatment, US, therapy, disease, and the most common words in the summary are: astrazeneca, drug, plc, comment, company, market, cancer, . One of the sentences in the summary was: Truqap in combination with Faslodex (fulvestrant) for the treatment of the most common type of breast cancer. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #drug #plc #comment #company #market #cancer.